➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:


Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Patent: 9,408,926

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,408,926
Title:KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
Abstract: The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K.sub.D<1 .mu.M), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.
Inventor(s): Arbogast; Christophe (Viuz-en-Sallaz, FR), Bussat; Philippe (Pers-Jussy, FR), Fan; Hong (Helen) (Shanghai, CN), Khurana; Sudha (Santa Clara, CA), Linder; Karen E. (Kingston, NJ), Marinelli; Edmund R. (Tucson, AZ), Nanjappan; Palaniappa (Princeton, NJ), Nunn; Adrian D. (Lambertville, NJ), Pillai; Radhakrishna K. (Cranbury, NJ), Pochon; Sibylle (Troinex, CH), Ramalingam; Kondareddiar (Stockbridge, GA), Shrivastava; Ajay (Princeton, NJ), Song; Bo (Princeton, NJ), Swenson; Rolf E. (Princeton, NJ), Von Wronski; Mathew A. (Geneva, CH), Yan; Feng (Grand-Lancy, CH)
Assignee: Bracco Suisse S.A. (Manno, CH)
Application Number:14/085,645
Patent Claims:see list of patent claims

Details for Patent 9,408,926

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Bracco Suisse S.A. (Manno, CH) 2022-03-01 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Bracco Suisse S.A. (Manno, CH) 2022-03-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.